Overview

Collection of Transplant Stem Cells for Plasma Cell Myeloma

Status:
Completed
Trial end date:
2018-01-11
Target enrollment:
Participant gender:
Summary
Background: - One beneficial treatment for plasma cell myeloma is high-dose chemotherapy followed by stem cell transplant. Researchers want to collect stem cells from the blood for later transplant. Objectives: - To collect stem cells for transplant as part of treatment for plasma cell myeloma. Eligibility: - Individuals at least 18 years of age who will have chemotherapy and stem cell transplant for plasma cell myeloma. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. - Participants will have filgrastim injections for 5 days before collection. This will move stem cells from the bone marrow to the blood. - Participants will have apheresis to collect the stem cells. - Participants who need additional apheresis procedures to collect stem cells will have filgrastim and a dose of plerixafor to improve the collection yield.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
JM 3100
Lenograstim
Plerixafor